Login to Your Account

Merrimack Consolidates MM-398 with $220M+ PharmaEngine Deal

By Tom Wall

Tuesday, May 10, 2011
Merrimack Pharmaceuticals Inc. consolidated its development and commercialization program for MM-398/PEP02 by acquiring rights for Europe and Asia from PharmaEngine Inc., of Taipei, Taiwan, for $10 million up front, a potential $210 million in milestones, and tiered royalties on sales.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription